News from Juventas Therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 18, 2014, 09:10 ET Juventas Therapeutics Presents Phase II Data at AHA Scientific Sessions That Shows JVS-100 is Safe, Potentially Effective in Patients with Critical Limb Ischemia

Juventas Therapeutics Inc., a privately-held, clinical-stage company developing novel therapies for treatment of cardiovascular disease, had...


Nov 12, 2014, 09:10 ET Juventas Therapeutics Phase II Clinical Study Results to be Presented at 2014 American Heart Association Scientific Sessions

 Juventas Therapeutics Inc., a privately-held, clinical-stage company developing novel therapies for treatment of cardiovascular disease, today...


Oct 28, 2014, 09:10 ET Juventas Therapeutics Strengthens Management Team with New Senior Vice President of Finance and Operations

 Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular...


Aug 12, 2014, 09:05 ET Juventas Therapeutics completes enrollment of Phase I/II RETRO-HF trial and demonstrates safety for retrograde infusion of JVS-100 in patients with heart failure

Juventas Therapeutics, Inc., a private clinical-stage company developing a drug-based approach to regenerative medicine today announced that it...


Jul 23, 2014, 10:11 ET Juventas Therapeutics strengthens leadership team by adding two industry veterans

Juventas Therapeutics, a clinical-stage biotechnology company developing a first-in-class regenerative gene therapy for treatment of heart failure...


May 06, 2014, 09:00 ET Juventas Therapeutics to Present Top-Line Interim Results from Phase II STOP-HF Trial in Late-Breaking Oral Presentation at European Society of Cardiology Heart Failure Congress

Juventas Therapeutics today announced that top-line interim data from its ongoing Phase II STOP-HF study will be presented in a late-breaking oral...


Feb 04, 2014, 09:00 ET Juventas Therapeutics initiates Phase II RETRO-HF clinical trial enrollment for patients with heart failure

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for the treatment of cardiovascular...


Dec 09, 2013, 09:35 ET Juventas Therapeutics initiates first clinical trial for retrograde infusion of a gene therapy to patients with heart failure

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease,...


Oct 28, 2013, 09:00 ET Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure

Juventas Therapeutics, a privately-held clinical-stage company developing novel therapies for treatment of cardiovascular disease, announced today...


Jan 28, 2013, 09:00 ET Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease...


Aug 20, 2012, 09:00 ET Juventas Therapeutics doses first patient in Phase II STOP-HF trial

Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease,...


Jul 16, 2012, 09:00 ET Juventas Therapeutics Raises $22.2 Million Series B Financing

 Juventas Therapeutics, a clinical-stage regenerative medicine company, announced today that it has closed a $22.2 million Series B financing...


May 15, 2012, 09:00 ET Juventas Therapeutics Enrolling Patients in Phase IIa STOP-CLI Clinical Trial

 Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular...


Jan 30, 2012, 09:00 ET Juventas Therapeutics Reports One Year Data From Phase I Heart Failure Clinical Trial

Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular...


Apr 26, 2011, 08:00 ET Juventas Therapeutics Completes Successful Phase I Clinical Trial for JVS-100 in Treatment of Patients with Heart Failure

Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that it has...


Apr 05, 2010, 08:00 ET Juventas Therapeutics Enrolling Phase I Clinical Trial of JVS-100 for Patients with Heart Failure

Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I...